Aneeka Nawar Fatema
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Aneeka Nawar Fatema has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
Abrar Wahab
Department of Public Health, North South University, Dhaka, 1229, Bangladesh
1 shared publication- Ahmed Hossain
College of Health Sciences, University of Sharjah, Sharjah, United Arab Emirates
1 shared publication - Ashmita Sapkota
School of Health & Allied Sciences, Pokhara University, Kaski, Nepal
1 shared publication - Dilshad Jahan
Department of Hematology, Asgar Ali Hospital, 111/1/A Distillery Road, Gandaria Beside Dhupkhola, Dhaka 1204, Bangladesh
1 shared publication Gias U. Ahsan
Department of Public Health, North South University, Dhaka, 1229, Bangladesh
1 shared publication- Hasan Al Banna
Institute of Social Welfare and Research, University of Dhaka, Dhaka 1000, Bangladesh
1 shared publication
Latest Publications
- Open Access
- 1 November 2020
- Published by Taylor & Francis in Risk Management and Healthcare Policy
- Vol. ume 13, 2707-2728
Convalescent Plasma Therapy for Management of COVID-19: Perspectives and Deployment in the Current Global Pandemic
The world is striving against the severe crisis of the COVID-19 pandemic. Healthcare professionals are struggling to treat their patients based on nonspecific therapies. Amidst this uncertainty, convalescent plasma therapy (CPT) has appeared to be an interim adjuvant therapy for severely ill patients of COVID-19 until long-term clinical trial treatment options are available. Considering the transfusion-related hazards, especially lung injuries and microbial transmission, where sensitivity is not ensured, rigorous trials should be conducted to determine this therapy’s efficacy. Moreover, the ratio of recovered cases to plasma donors is not satisfying, which questioning this therapy’s availability and accessibility. Although some countries are making the treatment free, the attributable cost mandates a justification for its suitability and sustainability. Our article aimed to review the published facts and findings of CPT’s effectiveness in lowering the mortality rate of COVID-19. This pandemic showed that healthcare systems worldwide need core reform. A unified global collaboration must align and coordinate to face the current pandemic and enhance world readiness for future outbreaks based on health equity and equality.
- 1 November 2020
- Published by Taylor & Francis in Risk Management and Healthcare Policy
- Vol. ume 13, 2707-2728
Open AccessConvalescent Plasma Therapy for Management of COVID-19: Perspectives and Deployment in the Current Global Pandemic
The world is striving against the severe crisis of the COVID-19 pandemic. Healthcare professionals are struggling to treat their patients based on nonspecific therapies. Amidst this uncertainty, convalescent plasma therapy (CPT) has appeared to be an interim adjuvant therapy for severely ill patients of COVID-19 until long-term clinical trial treatment options are available. Considering the transfusion-related hazards, especially lung injuries and microbial transmission, where sensitivity is not ensured, rigorous trials should be conducted to determine this therapy’s efficacy. Moreover, the ratio of recovered cases to plasma donors is not satisfying, which questioning this therapy’s availability and accessibility. Although some countries are making the treatment free, the attributable cost mandates a justification for its suitability and sustainability. Our article aimed to review the published facts and findings of CPT’s effectiveness in lowering the mortality rate of COVID-19. This pandemic showed that healthcare systems worldwide need core reform. A unified global collaboration must align and coordinate to face the current pandemic and enhance world readiness for future outbreaks based on health equity and equality.
- RetractedOpen Access
RETRACTED: Age and gender-specific antibiotic resistance patterns among Bangladeshi patients with urinary tract infection caused by Escherichia coli